news aktuell GmbH

nal von minden: Did my vaccine work? New rapid test for the determination of vaccination success.

Share
Am I really protected against the coronavirus now? This is a question asked by many after receiving a vaccination. The medtech company nal von minden from Moers in Germany has now developed a rapid test that can reliably detect antibodies against COVID-19 pathogens in blood. The NADAL® COVID-19 S1-NAb Test is now available all over Europe.

(Moers, Germany): “People want clarity once they been vaccinated against coronavirus: They want to know if it has worked“ says Thomas Zander, CEO of nal von minden GmbH. Depending on the particular vaccine used, the COVID-19 vaccines offer 70% or more protection from the disease – but not 100%.


If the vaccine has ‘worked’, the body produces human antibodies against the disease. “These antibodies ensure that, in the event of exposure, the disease pathogens – the coronaviruses – would be readily identified and quickly repelled. Rather like the police on alert.”

These antibodies can be found in human blood and, if present, are easily detectable. With the NADAL® COVID-19 S1-NAb Test, the process takes just a few minutes. Thomas Zander explains: “Our new rapid test for the detection of coronavirus antibodies can be carried out by your GP in the future, as the test is currently only for professional use. A tiny prick of the finger is enough. The little drop of blood is added to the accompanying test cassette, and results can be read within 15 minutes.”

The new rapid test has already been comprehensively studied in the USA and China. “In the USA and China the vaccination programmes are more progressed, so the first studies were carried out there,” says Zander. “Further quality studies at German research centres will follow shortly.” It has been confirmed that the antibody test works for all kinds of vaccines (BioNtech, AstraZeneca, Johnson&Johnson, Sinovac and Moderna).

Coronavirus vaccinations usually take place across two appointments, and the new rapid test can be carried out either two weeks after the first vaccination, or two weeks after the second, says Thomas Zander. “Those who produce an immune response following the first vaccine – which can cause, for example, mild cold-like symptoms – can first wait until after the second vaccination.” Of course, the test can also be carried out weeks or even months afterwards, as nobody yet knows how long the vaccinations protect us against coronaviruses.

Contacts

Gabriele Hellwig, info@hellwig-pr.de

Images

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform Plans to use innovative Bosch BioMEMS technology in PCR tests for multiresistant bacteria18.4.2024 10:15:00 CEST | Press release

Bosch and R-Biopharm are jointly investing 150 million euros in the development of new PCR tests and in marketing. PCR test for multiresistant gram-negative (MRGN) bacteria to be developed using novel BioMEMS technology. BioMEMS chips permit simultaneous testing of up to 250 genetic characteristics – in some cases, in less than 15 minutes. Darmstadt, Gerlingen, and Waiblingen, Germany – The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform. The two companies will invest a total of 150 million euros by the end of the decade. Within their strategic development and distribution partnership, the partners intend t

Elatec Brings Employee Badge for Apple Wallet to Users17.4.2024 08:45:03 CEST | Press release

Munich, April 17, 2024 – Elatec today announced it is bringing employee badge in Apple Wallet to its customers, enabling an organization’s employees or tenants to unlock access to locations and devices with a simple tap of their iPhone or Apple Watch. Powered by Elatec’s Mobile Credential Manager software, which works hand-in-hand with Elatec’s universal RFID readers, this brings together the world’s most powerful and versatile readers with the best mobile access system available. Employee badge in Apple Wallet helps deliver a convenient and contactless experience for users. Once enabled, employee badge in Apple Wallet allows users to seamlessly and securely add their employee badge to Apple Wallet, and hold their iPhone or Apple Watch near an NFC reader to unlock office doors, turnstiles, elevators and key card-protected amenity spaces — eliminating the need to open an app or present a traditional, plastic access key. With Express Mode, employees do not need to unlock their device to

National Research Center for Applied Cybersecurity ATHENE: Severe Vulnerabilities Discovered in Software to Protect Internet Routing12.4.2024 08:49:14 CEST | Press release

A research team from the National Research Center for Applied Cybersecurity ATHENE led by Prof. Dr. Haya Schulmann has uncovered 18 vulnerabilities in crucial software components of Resource Public Key Infrastructure (RPKI). RPKI is an Internet standard meant to protect Internet traffic from being hijacked by hackers. By now, all affected vendors provided patches for their products. The vulnerabilities could have had devastating consequences: Internet hijacks have already been exploited, e.g., for phishing passwords and other sensitive information, tricking certificate authorities into issuing fraudulent Web certificates, stealing cryptocurrency, distributing malware, and poisoning caches of DNS servers.

Dr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment10.4.2024 11:00:00 CEST | Press release

The launch in Germany through its step-down subsidiary betapharm marks Dr. Reddy's entry into digital therapeutics in Europe. Nerivio® is the first REN (wearable, FDA-cleared, and CE-marked for acute and/or prevention migraine (with or without aura) treatment for adults and adolescents (≥ 12 years). Nerivio® is worn on the upper arm during treatment and controlled by a smartphone app, making it comfortable and portable. Starting with Germany, followed by Spain and the UK, Dr. Reddy's plans to further increase access to Nerivio® in European countries.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye